The United States reached a deal for up to $2.1 billion with pharmaceutical firms Sanofi and GlaxoSmithKline, for the development and (if it is effective) production of up to 100 million doses of a potential COVID-19 vaccine, based on proteins found on SARS-CoV-2. Sanofi’s effort is now a part of Operation Warp Speed, joining the Pfizer-BioNTech, AstraZeneca-University of Oxford, and Novavax Inc. vaccines, as well as the Regeneron antibody treatment.
US and Canada Public
Another Vaccine Candidate Joins Operation Warp Speed
About the author
Latest articles
Related coverage
-
In-Depth
White House Lighting a Crypto Fuse Under Volatile Treasury Market
-
In-Depth
The Battle in the United States: LaRouche’s Physical Economy vs. Clones of Soros and Schacht
-
In-Depth Paid
U.S. Presidential Election: Stunning Revolt Against the Establishment, But They Still Don’t Get It
-
weekly Paid
Ukraine’s ‘Molfar’ Hit List Puts Bullseye on J.D. Vance While Congress Pushes Back
